The combination of strong revenue growth, successful $130 million capital raise, and clear path to profitability in 2026 makes PHAT a compelling biotech investment. Traders should monitor prescription growth trends and the company's ability to meet its 2026 guidance.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $13.56entry
- T+1 · 9mo ago −7.37%α −6.92% · $12.56
- T+5 · 9mo ago −20.80%α −19.67% · $10.74
- T+20 · 8mo ago −20.43%α −14.03% · $10.79
- T+60 · 6mo ago −14.60%α −22.35% · $11.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phathom Pharmaceuticals reported strong financial results for Q4 and full year 2025, with revenue of $57.6 million in Q4 and $175.1 million for the full year, representing a 217% increase from 2024. The company also announced $130 million in gross proceeds from an equity offering and provided 2026 guidance with expected operating profitability beginning in Q3 2026.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $57.6 million, up from $29.7 million in Q4 2024
- Full year 2025 revenue was $175.1 million, a 217% increase from $55.3 million in 2024
- Company completed $130 million equity offering in January 2026
- Provided 2026 guidance with net revenues of $320-345 million and expected operating profitability beginning in Q3 2026
- Over 1.1 million total VOQUEZNA prescriptions filled as of February 13, 2026
Financial Impact
Revenue increased 217% year-over-year to $175.1 million in 2025, with 2026 guidance projecting $320-345 million in net revenues
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VOQUEZNA | $175.1M | +217.0% |
Risk Factors
- Forward-looking statements about achieving profitability in Q3 2026
- Dependence on continued VOQUEZNA prescription growth
- Potential competition in the GERD treatment market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073377 |
| Document: d119012d8k.htm | 0001193125-26-073377 |
| Document: 0001193125-26-073377-index-headers.html | 0001193125-26-073377 |
| Document: 0001193125-26-073377-index.html | 0001193125-26-073377 |
| Document: 0001193125-26-073377.txt | 0001193125-26-073377 |
Track record
16 reports on PHAT
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +36.43% at T+60 after the Jul 30, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $6.28 Now $5.88 −6.37% settles Nov 18
- Nov 2, 202614d ago SC 13D/A Neutral 3/10 Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
- Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
- Jul 30, 202615w ago 8-K Mixed 5/10 No price data
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers